The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Amphotericin B nephrotoxicity
Abstract
The use of amphotericin B limited by dose-dependent nephrotoxicity. Elevated creatinine associated with amphotericin B is not only a marker for renal dysfunction, but is also linked to an increase in hospital costs and a substantial risk for the use of haemodialysis and a higher mortality rate. Therefore, amphotericin B nephrotoxicity is not a benign complication and its prevention is essential. Several manipulations have been proposed to minimize amphotericin B-induced nephrotoxicity. Mannitol and frusemide administration are reported to be protective based on anecdotal observational reports. Small prospective and randomized trials do not suggest a protective effect. Three new formulations have been developed in attempts to improve both efficacy and tolerability: amphotericin B in a lipid complex (ABLC; Abelcet); amphotericin B colloidal dispersion; and liposomal amphotericin B (AmBisome). Three prospective randomized studies have clearly shown that AmBisome is less nephrotoxic than amphotericin B. In a double-blind randomized trial significantly fewer patients receiving AmBisome had nephrotoxic effects. This significant reduction in azotaemia was also observed among subgroups of patients receiving concomitant therapy with nephrotoxic agents. Moreover, there were fewer patients with hypokalaemia in the group receiving AmBisome. A recent multicentre double-blind study has shown that AmBisome (3 or 5 mg/kg/day) has a better safety profile than Abelcet (5 mg/kg). Patients in both AmBisome treatment groups experienced less chills/rigors, less nephrotoxicity based on a doubling of serum creatinine, and fewer toxic reactions resulting in discontinuation of therapy. In conclusion, amphotericin B nephrotoxicity is observed frequently. It clearly increases patient mortality. Nephrotoxicity must be recognized early, based on tubular abnormalities and a mild increase in serum creatinine. Its prevention relies on the detection and suppression of risk factors and the use of AmBisome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 439
Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Louise, W., Bowden, R., Anaissie, E., Hiemenz, J., & Lister, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313498 · Cited by 368
Leenders, A. C. A. P., Daenen, S., Jansen, R. L. H., Hop, W. C. J., Lowenberg, B., Wijermans, P. W., Cornelissen, J., Herbrecht, R., Lelie, H. V. D., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 319
White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R., Goldman, M., van Burik, J., McCabe, A., Lin, J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514672 · Cited by 303
Sharkey, P. K., Graybill, J. R., Johnson, E. S., Hausrath, S. G., Pollard, R. B., Kolokathis, A., Mildvan, D., Fan-Havard, P., Eng, R. H. K., Patterson, T. F., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.315 · Cited by 197
Moreau, P., Milpied, N. J., Fayette, N., Ramée, J., & Harousseau, J. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/30.4.535 · Cited by 118
On the nephrotoxicity of amphotericin B in man
Bell, N. H., Andriole, V. T., Sabesin, S. M., & Utz, J. P. (1962) · The American Journal of Medicine · doi:10.1016/0002-9343(62)90277-2 · Cited by 76
Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B
Ellis, M. E., Alhokail, A., Clink, H. M., Padmos, M. A., Ernst, P., Spence, D. G., Tharpe, W., & Hillier, V. F. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.1.172 · Cited by 76
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507530 · Cited by 345
Cinnamaldehyde and its derivatives, a novel class of antifungal agents
Shreaz, S., Wani, W. A., Behbehani, J. M., Raja, V., Irshad, M., Karched, M., Ali, I., Siddiqi, W. A., & Hun, L. T. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.05.016 · Cited by 345
Metadata
- Authors
- Deray, G.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 49
- Issue
- suppl_1
- Pages
- 37-41
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2321438510
- Cited by
- 400
- References
- 14
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amphotericin B nephrotoxicity. https://app.cochat.ai/papers/10.1093/jac/49.suppl_1.37
- The paper
- Deray, G. (2002). Amphotericin B nephrotoxicity. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/49.suppl_1.37
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.